Related Experiment Video

Updated: Apr 16, 2026

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.6K

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications

Ramzi Abbassi1, Terrance G Johns2, Michael Kassiou3

  • 1Department of Pharmacology, School of Medical Sciences, University of Sydney, NSW 2006, Australia.

Pharmacology & Therapeutics
|March 22, 2015
PubMed

Insights

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is crucial for brain development and implicated in cancers. Research is advancing to develop DYRK1A inhibitors for treating related diseases.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protein kinases are key drug targets, yet Dual-specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) remains understudied.
  • DYRK1A is vital for neuronal progenitor cell proliferation and differentiation during development.
  • DYRK1A overexpression is linked to various diseases, including hematological and brain cancers.

Purpose of the Study:

  • To review molecular studies on DYRK1A signaling in pathological functions.
  • To highlight drug discovery efforts for DYRK1A inhibitors.
  • To discuss the therapeutic potential of DYRK1A inhibitors for DYRK1A-dependent diseases.

Main Methods:

  • Literature review of molecular studies on DYRK1A.
  • Analysis of drug discovery efforts and disclosed inhibitor classes.
  • Evaluation of DYRK1A's role in disease pathogenesis.

Main Results:

  • Accumulating evidence links DYRK1A signaling to pathological functions in various diseases.
  • Significant progress has been made in developing potent and selective DYRK1A inhibitors.
  • Several classes of DYRK1A inhibitors show promise as therapeutic agents.

Conclusions:

  • DYRK1A is an important target for drug development in cancer and other diseases.
  • Targeted inhibition of DYRK1A represents a promising therapeutic strategy.
  • Further research into DYRK1A inhibitors could lead to novel treatments for DYRK1A-dependent pathologies.
Keywords:
Alzheimer’s diseaseCancerDYRK1ADown syndromeDual-specificity kinasesKinase inhibitors

More Related Videos

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

8.1K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.9K

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
89.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K